首页|Unlocking the potential:advancements and future horizons in ROR1-targeted cancer therapies
Unlocking the potential:advancements and future horizons in ROR1-targeted cancer therapies
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
维普
While receptor tyrosine kinase-like orphan receptor 1(ROR1)is typically expressed at low levels or absent in normal tissues,its expression is notably elevated in various malignant tumors and conditions,including chronic lymphocytic leukemia(CLL),breast cancer,ovarian cancer,melanoma,and lung adenocarcinoma.This distinctive feature positions ROR1 as an attractive target for tumor-specific treatments.Currently,several targeted drugs directed at ROR1 are undergoing clinical development,including monoclonal antibodies,antibody-drug conjugates(ADCs),and chimeric antigen receptor T-cell therapy(CAR-T).Additionally,there are four small molecule inhibitors designed to bind to ROR1,presenting promising avenues for the development of PROTAC degraders targeting ROR1.This review offers updated insights into ROR1's structural and functional characteristics,embryonic development implications,cell survival signaling pathways,and evolu-tionary targeting strategies,all of which have the potential to advance the treatment of malignant tumors.
Lin Li、Weixue Huang、Xiaomei Ren、Zhen Wang、Ke Ding、Linxiang Zhao、Jinwei Zhang
展开 >
State Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education,Shenyang Pharmaceutical University,Shenyang 110016,China
State Key Laboratory of Chemical Biology,Research Center of Chemical Kinomics,Shanghai Institute of Organic Chemistry,Chinese Academy of Sciences,Shanghai 200032,China
万方数据
维普
